Business
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your Mouth" cladribine formulation, built on the Company's ...
About this update from Bionxt Solutions Inc
[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your Mouth" cladribine formulation, built on the Company's proprietary oral dissolvable film (ODF) drug-delivery system. The technology is designed for rapid, sublingual (under-the-tongue) absorption of medication and aims to improve treatment access and comfort for people living with multiple sclerosis (MS). BioNxt's lead program, BNT23001, is being developed as a swallow-free alternative to cladribine tablets, which generated USD 1.28 billion in global sales in 2024.","length":706,"tagName":"p"},{"type":"text","content":"Cladribine (Mavenclad®) is an established therapy for MS; however, many patients struggle with difficulty swallowing tablets, a symptom that is both common and often under-recognized. For these individuals, pill-based medication can lead to coughing, choking, anxiety, and missed doses - all of which reduce treatment consistency and therapeutic effectiveness.","length":360,"tagName":"p"},{"type":"text","content":"BioNxt's "Melt in Your Mouth" ODF is engineered to dissolve in seconds under the tongue, eliminating the need to swallow and offering a needle-free, patient-friendly method of administration. The approach aims to enhance treatment adherence, safety, and overall quality of life for MS patients who face challenges with tablet-based medication.","length":357,"tagName":"p"},{"type":"text","content":"Swallowing Difficulties: A Hidden Barrier in Multiple Sclerosis Treatment","length":73,"tagName":"p"},{"type":"text","content":"Swallowing problems (dysphagia) are common in MS but often overlooked. A recent meta-analysis of more than 10,800 MS patients found that approximately 45% experience dysphagia during the course of their disease (2023, Journal of Clinical Neuroscience). Additional clinical studies using instrumental swallowing assessments have reported abnormalities in over 50% of patients, including cases not detected through self-report.","length":425,"tagName":"p"},{"type":"text","content":"For these individuals, tablets may feel "stuck," provoke coughing or choking, or require repeated attempts to swallow - turning a simple daily task into a persi...